BioMarin Pharmaceutical | BMRN - Nettoeinkommen

Aktienkurs
57.07
Täglich Wechseln
-0.36 -0.63%
Monatlich
-7.70%
Jährlich
-20.20%
Q1 Prognose
56.74




Nettoeinkommen Veränderung Datum
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
Agios Pharmaceuticals USD -108.04M 4.61M 2025-12
Alnylam Pharmaceuticals USD 186.42M 64.66M 2025-12
Amgen USD 1.33B 1.88B 2025-12
Bayer EUR -3.76B 2.79B 2025-12
Biogen USD 466.5M 168.3M 2025-09
BioMarin Pharmaceutical USD -46.57M 15.83M 2025-12
Gilead Sciences USD 2.18B 869M 2025-12
Incyte USD 299.28M 124.89M 2025-12
Insmed USD -328.48M 41.54M 2025-12
Ionis Pharmaceuticals USD -229M 100.39M 2025-12
Moderna USD -200M 625M 2025-09
Neurocrine Biosciences USD 209.5M 102M 2025-09
PTC Therapeutics USD -134.96M 150.86M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Roche Holding CHF 5.47B 1.76B 2025-12
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Sanofi EUR -801M 3.6B 2025-12
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
Ultragenyx Pharmaceutical USD -129M 51.41M 2025-12
United Therapeutics USD 364.3M 25.6M 2025-12
Vertex Pharmaceuticals USD 1.19B 108.2M 2025-12